Fatty acid-binding proteins (FABPs), a family of lipid chaperones, contribute to systemic metabolic regulation via several lipid signaling pathways. Fatty acid-binding protein 4 (FABP4), known as adipocyte FABP (A-FABP) or aP2, is mainly expressed in adipocytes and macrophages and plays important roles in the development of insulin resistance and atherosclerosis in relation to metabolically driven low-grade and chronic inflammation, referred to as 'metaflammation'. FABP4 is secreted from adipocytes in a non-classical pathway associated with lipolysis and acts as an adipokine for the development of insulin resistance and atherosclerosis. Circulating FABP4 levels are associated with several aspects of metabolic syndrome and cardiovascular disease. Ectopic expression and function of FABP4 in cells and tissues are also related to the pathogenesis of several diseases. Pharmacological modification of FABP4 function by specific inhibitors, neutralizing antibodies or antagonists of unidentified receptors would be novel therapeutic strategies for several diseases, including obesity, diabetes mellitus, atherosclerosis and cardiovascular disease. Significant roles of FABP4 as a lipid chaperone in physiological and pathophysiological conditions and the possibility of FABP4 being a therapeutic target for metabolic and cardiovascular diseases are discussed in this review.

Key words: Adipocyte, Macrophage, Endothelium, Atherosclerosis, Insulin resistance, Adipokine, aP2, A-FABP, Mal1, E-FABP

Introduction

Several factors, including genetics, behavior and environment, cause visceral fat accumulation, which is associated with obesity-related metabolic disorders. In the adipose tissue of obesity, adipocytes and several immune cells, especially macrophages, interact with each other and induce insulin resistance, diabetes mellitus, dyslipidemia and hypertension, leading to the development of atherosclerosis. Adipose tissue can secrete several hormonal bioactive molecules called adipokines, including adiponectin, leptin, resistin and fatty acid-binding protein 4 (FABP4). It has recently been reported that FABP4, mainly expressed in adipocytes and macrophages, plays significant roles in the development of insulin resistance and atherosclerosis via both intracellular and extracellular effects (Fig. 1).

Fatty Acid-Binding Proteins (FABPs)

Fatty acid trafficking in cells affects many aspects of cellular function. Fatty acids act both as an energy source and as signals for metabolic regulations including gene expression, inflammatory and metabolic responses, and growth and survival pathways. Fatty acid-binding proteins (FABPs), a family of intracellular lipid chaperones, regulate lipid trafficking and responses in cells and are linked to metabolic and inflammatory pathways. FABPs are abundantly expressed 14-15-kDa proteins that reversibly bind hydrophobic ligands, such as long-chain fatty acids and other lipids. It has been proposed that FABPs actively facilitate the transport of fatty acids to specific organelles in the cell for lipid oxidation in the mitochondrial or peroxisome, transcriptional regulation in the nucleus, signaling, trafficking and membrane synthesis in the endoplasmic reticulum (ER), and regula-
Expression of FABP4

Expression of FABP4 is highly induced during adipocyte differentiation and is transcriptionally controlled by peroxisome proliferator-activated receptor (PPAR) γ agonists, fatty acids, insulin and dexamethasone. Expression of FABP4 is also induced during differentiation from monocytes to macrophages and by treatment with lipopolysaccharide (LPS), phorbol 12-myristate 13-acetate, PPARγ agonists, oxidized low-density lipoprotein and advanced glycation end products. Similar to macrophages, monocyte-derived dendritic cells express FABP4 during differentiation. Conversely, treatment with omega-3 fatty acids and sitagliptin decreases FABP4 expression in 3T3-L1 adipocytes. In macrophages, treatment with atorvastatin and metformin reduces FABP4 expression, indicating different ligand selectivity and binding affinity for fatty acids because of structural differences.

At least 9 different FABP isoforms have been identified. The FABP family includes liver (L-FABP/FABP1), intestinal (I-FABP/FABP2), heart (H-FABP/FABP3), adipocyte (A-FABP/FABP4/aP2), epidermal (E-FABP/FABP5/mal1), ileal (Il-FABP/FABP6), brain (B-FABP/FABP7), myelin (M-FABP/FABP8), and testis (T-FABP/FABP9) isoforms. FABPs have about 15% to 70% sequence identity between different isoforms and have almost the same three-dimensional structures showing a cap by the helix–loop–helix region and two orthogonal five-stranded β-sheets by a 10-stranded anti-parallel β-barrel structure. The fatty acid-binding pocket is located inside the β-barrel. The opening of the binding pocket is framed on one side by the N-terminal helix–loop–helix cap domain, and usually one long-chain fatty acid can be bound to the interior cavity of FABPs except for FABP1, which can bind two fatty acids. Each FABP has different ligand selectivity and binding affinity for fatty acids because of structural differences.

Fig. 1. FABP4-mediated insulin resistance and atherosclerosis in obesity

Several factors, including genetics, stress, excess nutrients and lack of exercise, induce obesity characterized by visceral fat accumulation. In adipose tissue, adipocytes and several immune cells, especially macrophages, interact with each other and induce insulin resistance, diabetes mellitus (DM), dyslipidemia (DL) and hypertension (HT), leading to the development of atherosclerosis. Fatty acid-binding protein 4 (FABP4), which is mainly expressed in adipocytes and macrophages, plays significant roles in the development of insulin resistance and atherosclerosis via both intracellular and extracellular effects. EC, endothelial cell; PVAT, perivascular adipose tissue; SMC, smooth muscle cell.
expression. FABP4 also triggers the ubiquitination and subsequent proteasomal degradation of PPARγ and consequently inhibits PPARγ-related functions, thereby providing a negative feedback loop.

The upstream of the 5′ flanking region of the mouse FABP4 gene contains a direct repeat-1 (DR-1)-type PPAR response element (PPRE) at -5.3 kb, a glucocorticoid response element (GRE) at -393 to -385 bp, a CCAAT/enhancer-binding protein (C/EBP) binding site at -149 to -130 bp, and an activator protein-1 (AP-1) site at -122 to -116 bp. A functionally significant genetic variation at the FABP4 locus in humans, T-87C polymorphism, has been reported to result in decreased FABP4 expression in adipose tissue due to alteration of the C/EBP and reduced transcriptional activity of the FABP4 promoter.

FABP4 is also expressed in capillary and venous, but not arterial, endothelial cells in a normal condition. Treatment with vascular endothelial growth factor (VEGF)-A via VEGF-receptor-2 or basic fibroblast growth factor (bFGF) induces FABP4 expression in endothelial cells, and FABP4 in endothelial cells promotes angiogenesis. Interestingly, cellular senescence and oxidative stress induce FABP4 expression in microvascular endothelial cells. Furthermore, FABP4 is ectopically induced in injured arterial endothelial cells.

**Fatty Acid Affinity of FABP4**

In an assay for fatty acid-binding affinity, FABP4 generally had higher affinity and selectivity for long-chain fatty acids than did albumin. Linoleic acid and α-linolenic acid, essential polyunsaturated fatty acids, had the highest affinity for FABP4 under a basal condition, suggesting that transport of linoleic acid and α-linolenic acid is a physiological role of FABP4. Under an oxidative condition, the affinity of FABP4 for most of the fatty acids except for palmitic acid was decreased, indicating that palmitic acid, a saturated fatty acid, has relatively high affinity for FABP4 under a specific condition such as obesity-induced oxidative stress.

**Function of FABP4 in the Cell**

Similar to other FABPs, FABP4 is thought to carry fatty acids to several organelles in the cell such as the mitochondrion, peroxisome, ER and nucleus. The primary sequence of FABP4 does not have a typical nuclear localization signal (NLS) or nuclear export signal (NES) as a potential functional domain. However, the NLS and NES could be found in the three-dimensional structure of FABP4. The NLS in FABP4 is activated by closure of the portal loop and perturbation of a swinging doorway region. Non-activating ligands, such as oleic acid and stearic acid, protrude from the portal and prevent its closure, leading to masking of the NLS, while activating ligands, such as linoleic acid, troglitazone and anilinonaphthalene sulphonate, expose the NLS.

**Phenotype of FABP4 Deficiency**

FABP4-deficient mice with high-fat diet-induced and genetic obesity show reduced insulin resistance, but there is no effect of FABP4 on insulin sensitivity in lean mice. Knockdown of the Fabp4 gene by RNA interference in dietary obese mice increases body weight and fat mass without significant changes in glucose and lipid homeostasis, being similar to the phenotype of FABP4 heterozygous knockout mice on a high-fat diet. The remaining expression of FABP4 might maintain some parts of FABP4 function.
FABP4 is abundant in the cytosolic fraction of adipocytes and can bind one long-chain fatty acid (FA), including palmitic acid (PA), stearic acid (SA), oleic acid (OA), linoleic acid (LA) or α-linolenic acid (ALA). FABP4 facilitates the transport of FAs to specific organelles in the cell such as the mitochondrion, peroxisome, endoplasmic reticulum (ER) and nucleus, regulates enzyme activity, and stores excess FA as lipid droplets in adipocytes. LA-bound, but not SA- or OA-bound, FABP4 can be moved into the nucleus by unmasking of the nuclear localization signal (NLS). The protein-protein interactions of FABP4 with hormone-sensitive lipase (HSL) and comparative gene identification-58 (CGI-58), a potent co-activator of adipose triglyceride lipase (ATGL), regulate intracellular triglyceride hydrolysis, and FABP4 is secreted from adipocytes in a non-classical pathway associated with lipolysis. FABP4 in macrophages inhibits the peroxisome proliferator-activated receptor γ (PPARγ)-liver X receptor α (LXRα)-ATP-binding cassette A1 (ABCA1) pathway and induces inflammatory responses through activation of the inhibitor of nuclear kappa B kinase (IKK)-nuclear factor-kappa B (NF-κB) and c-Jun N-terminal kinase (JNK)-activator protein-1 (AP-1) pathways. FABP4 is ectopically induced in injured arterial endothelial cells (ECs). Macrophages and ECs can also secrete FABP4. Secreted FABP4 may act as a carrier of LA and ALA, essential polyunsaturated FAs, to organs because of high affinities for FABP4 under normal conditions. Circulating FABP4 may affect several responses in target cells, including macrophages, ECs, smooth muscle cells (SMCs), adipocytes and other cells, through unidentified receptor-mediated effects in bound FA-dependent and -independent manners and/or possible internalization of FABP4 into the cell. Obesity and increased visceral fat promote oxidative stress. An oxidative stress condition can induce conformational change of the FABP4 structure and decrease affinity of most of the FAs, except for PA, for FABP4. Under a specific condition such as obesity-induced oxidative stress, PA would have relatively high affinity for FABP4, leading to PA-dependent inflammatory responses through unidentified receptors of PA-bound FABP4 and/or delivery of PA to toll-like receptor 4 (TLR4). FABP4 deficiency protects against atherosclerosis in apolipoprotein E (ApoE)-deficient mice. FABP4 in macrophages increases accumulation of cholesterol ester and foam cell formation via inhibition of the PPARγ-liver X receptor α (LXRα)-ATP-binding cassette A1 (ABCA1) pathway and induces inflammatory responses through activation of the inhibitor of nuclear kappa B kinase (IKK)-nuclear factor-kappa B (NF-κB) and c-Jun N-terminal kinase (JNK)-AP-1 pathways. Furthermore, the lack of FABP4 in macrophages decreases redox signaling and inflammasome activation via upregulation of uncoupling protein 2 (UCP2) and sirtuin 3 (SIRT3). FABP4 in dendritic cells also regulates the IKK-NF-κB pathway and T cell priming.
Secretion of FABP4

FABP4 lacks a signal peptide in the N-terminal sequence, which is necessary for the classical secretory pathway, i.e., ER-Golgi-dependent secretion. However, FABP4 is secreted from adipocytes in a non-classical secretion pathway associated with lipolysis, a series of intracellular triglyceride hydrolysis mediated by ATGL, HSL and monoacylglycerol lipase (MGL). Secrecion of FABP4 is also regulated by an intracellular calcium-dependent pathway. Furthermore, FABP4 is secreted partially by microvesicles derived from adipocytes, an established mechanism for unconventional secretion from adipocytes. However, the release of FABP4 via adipocyte-derived microvesicles is a small fraction and conveys a minor activity. In addition, unconventional secretion of FABP4 by endosomes and secretory lysosomes has recently been reported. It has also been confirmed that FABP4 is secreted from macrophages and vascular endothelial cells, which may be activated by inflammatory responses by FABP4. Taken together, circulating FABP4 secreted from adipocytes, macrophages and vascular endothelial cells seems to not only carry fatty acids to organs but also act as a bioactive molecule in several target cells, including macrophages, endothelial cells, smooth muscle cells, adipocytes and other cells (Fig. 2).

FABP4 as a Bioactive Molecule

FABP4 secreted from adipocytes, macrophages and endothelial cells may have bioactive effects since direct effects of exogenous FABP4 have been demonstrated in various types of cells. Exogenous FABP4 enhances hepatic glucose production in vivo and in vitro, induces endoplasmic reticulum stress in HepG2 liver cells, inhibits activation of endothelial nitric oxide synthase (eNOS) in vascular endothelial cells, increases proliferation/migration of vascular smooth muscle cells, decreases cardiomyocyte contraction in vitro, potentiated glucose-stimulated insulin secretion in pancreatic β cells, and increases breast cancer cell proliferation.

Obesity and increased visceral fat have been reported to promote oxidative stress. FABP4 preferentially binds linoleic acid and α-linolenic acid for transport of essential polyunsaturated fatty acids in a normal condition, but the affinity of FABP4 would be changed to prefer binding palmitic acid, a saturated fatty acid, probably via conformation change of FABP4 structure, in a condition of obesity-induced oxidative stress (Fig. 2). Microarray analysis using macrophages treated with recombinant FABP4 in the presence and absence of palmitic acid demonstrated fatty acid-dependent and -independent effects of exogenous FABP4. Notably, treatment of macrophages with recombinant FABP4 in the presence, but not the absence, of palmitic acid significantly increased inflammatory responses, including chemokine signaling and TNFα- NF-κB signaling pathways. Furthermore, activation of palmitic acid-dependent inflammatory responses by FABP4 was observed in not only in macrophages but also endothelial cells and vascular smooth muscle cells.

Circulating FABP4 Level

The concentration of FABP4 is highest among levels of FABP1-5 under a physiological condition in a general population without medication. FABP4 level is significantly higher in females than in males, possibly due to the larger amount of body fat in females than in males since there is an independent and strong correlation between FABP4 level and adiposity. In addition, androgen may partially contribute to the gender difference in serum FABP4 levels, being consistent with FABP4 secretion from adipocytes via β-adrenergic-mediated lipolytic mechanisms. Loss of body weight by exercise training and bariatric surgery induces a significant reduction in FABP4 concentrations.

Gene and protein expression levels of FABP4.
have been reported to be higher in subcutaneous adipose tissue than in visceral adipose tissue of both lean and obese subjects [77], but associations of subcutaneous adipose tissue and visceral adipose tissue assessed by multidetector computed tomography with circulating FABP4 levels were reported to be almost the same [78].

One possible reason for the discrepancy is that visceral adipose tissue is more metabolically active and sensitive to lipolysis than is subcutaneous adipose tissue [79], leading to the predominant contribution of visceral adipose tissue to the lipolysis-mediated secretion and circulating level of FABP4. The main source of circulating FABP4 is adipocytes rather than macrophages and endothelial cells [54, 62]. However, it has been reported that circulating FABP4 was detected in patients with lipodystrophy despite adipose tissue loss in contrast to other adipokines including leptin and adiponectin [80].

Multiplex proteomics demonstrated that FABP4 level was strongly associated with kidney function decline over a period of 5 years [81]. Serum FABP4 level was shown to be negatively correlated with estimated glomerular filtration rate [80], suggesting that FABP4 is eliminated from circulation mainly by renal clearance. It has recently been reported that circulating FABP4 is eliminated by the kidney via glomerular filtration followed by megalin-mediated reabsorption [69]. FABP4 level in hemodialysis patients with end-stage kidney disease was about 20-times higher than that in controls with normal renal function and was decreased by 57.2% after hemodialysis [82].

Increased circulating FABP4 levels have been shown to be associated with obesity [71], metabolic syndrome [83], insulin resistance [70, 84], type 2 diabetes mellitus [85], hypertension [86], dyslipidemia [87], atherosclerosis [88], left ventricular diastolic dysfunction [89] and heart failure [90] (Fig. 3). Xanthine oxidoreductase (XOR), a rate-limiting and catalyzing enzyme of uric acid formation in purine metabolism, is involved in an increase in reactive oxygen species [91], and plasma XOR activity has been shown to be a novel biomarker of metabolic disorders [92, 93]. A cohort study demonstrated that plasma XOR activity is independently associated with levels of adipokines, including FABP4 [94]. Circulating FABP4 is independently associated with the level of PCSK9, which binds to and degrades the low-density lipoprotein (LDL) receptor, suggesting associations with hypercholesterolemia and cardiovascular risk [95]. Furthermore, the basal FABP4 level is independently associated with change in carotid intima-media thickness, a marker of atherosclerosis, per year, indicating that FABP4 level predicts progress of atherosclerosis [96]. It has also been reported that serum FABP4 level predicts long-term cardiovascular events and mortality [82, 97-99].

Perivascular adipose tissue and epicardial fat have recently been proposed to influence vascular function and the pathogenesis of vascular disease [100, 101]. FABP4 mRNA expression in epicardial adipose tissue is profoundly increased compared with its expression in paraaortic adipose tissue in patients with metabolic syndrome [102]. FABP4, mainly derived from epicardial fat, is locally enrich in the pericardial cavity of cardiovascular disease patients [103]. The coronary veno-arterial difference in FABP4 levels in the aortic root and coronary sinus was shown to be an independent predictor of the severity of coronary stenosis after adjustment of conventional risk factors [35]. FABP4 levels are significantly elevated during the early hours after onset of acute myocardial infarction and are robustly increased in out-of-hospital cardiac arrest survivors, probably due to rapid lipolytic release of FABP4 from epicardial fat by adrenergic overdrive that accompanies acute cardiovascular disease [104].

Several drugs can modify circulating FABP4 levels (Fig. 3). Treatment with atorvastatin [105], a hydroxymethylglutaryl-CoA reductase inhibitor, several angiotensin II receptor blockers [106], omega-3 fatty acid ethyl esters containing eicosapentaenoic acid and docosahexaenoic acid [93], and sitagliptin [70], a dipeptidyl peptidase-4 inhibitor, reduces FABP4 concentrations. On the other hand, treatment with pioglitazone, a PPARγ agonist known as an insulin-sensitizing thiazolidinedione, increases FABP4 levels [107], presumably due to direct activation of PPARγ since the FABP4 gene promoter includes the PPRE [24, 25]. Treatment with canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, paradoxically increased serum FABP4 level in some diabetic patients despite amelioration of glucose metabolism and adiposity reduction, possibly via induction of catecholamine-induced lipolysis in adipocytes, and patients in whom FABP4 level was increased by canagliflozin had significantly smaller improvements of insulin resistance and hemoglobin A1c than did patients with decreased FABP4 level [108]. The increased FABP4 induced by PPARγ agonists or SGLT2 inhibitors may act as a carrier of linoleic acid and α-linolenic acid, as a physiological function. Therefore, it is important to enforce diet therapy for reducing accumulation of visceral fat and to prevent binding of FABP4 to palmitic acid, especially in the treatment with a PPARγ agonist and/or an SGLT2 inhibitor.

**Ectopic Expression of FABP4**

FABP4 is expressed in endothelial cells of capillaries and small veins but not arteries under a physio-
**Fig. 3.** Chain of FABP4-associated pathological conditions

FABP4 is expressed not only in adipocytes and macrophages but also in several types of tissues and cells under physiological and pathophysiological conditions and may contribute to several aspects of metabolic and cardiovascular diseases as well as renal, respiratory, neurological, gynecological and oncological diseases. Several drugs, including a statin, eicosatetraenoic acid (EPA)/docosahexaenoic acid (DHA) agent, angiotensin II receptor blocker (ARB) and dipeptidyl peptidase 4 inhibitor (DPP4i), can decrease FABP4 levels. Specific inhibitors and neutralizing antibodies of FABP4 and antagonists of unidentified FABP4 receptors may be candidates of therapeutic strategies for several FABP4-associated diseases.

FABP4 is expressed not only in adipocytes and macrophages but also in several types of tissues and cells under physiological and pathophysiological conditions and may contribute to several aspects of metabolic and cardiovascular diseases as well as renal, respiratory, neurological, gynecological and oncological diseases. Several drugs, including a statin, eicosatetraenoic acid (EPA)/docosahexaenoic acid (DHA) agent, angiotensin II receptor blocker (ARB) and dipeptidyl peptidase 4 inhibitor (DPP4i), can decrease FABP4 levels. Specific inhibitors and neutralizing antibodies of FABP4 and antagonists of unidentified FABP4 receptors may be candidates of therapeutic strategies for several FABP4-associated diseases.

**Fig. 3.** Chain of FABP4-associated pathological conditions

FABP4 is expressed not only in adipocytes and macrophages but also in several types of tissues and cells under physiological and pathophysiological conditions and may contribute to several aspects of metabolic and cardiovascular diseases as well as renal, respiratory, neurological, gynecological and oncological diseases. Several drugs, including a statin, eicosatetraenoic acid (EPA)/docosahexaenoic acid (DHA) agent, angiotensin II receptor blocker (ARB) and dipeptidyl peptidase 4 inhibitor (DPP4i), can decrease FABP4 levels. Specific inhibitors and neutralizing antibodies of FABP4 and antagonists of unidentified FABP4 receptors may be candidates of therapeutic strategies for several FABP4-associated diseases.
FABP4 in CVD and Metabolic Diseases

FABP4 as a Therapeutic Target

Several series of FABP4 inhibitors have been synthesized. The specific FABP4 inhibitor BMS309403 is an orally active small molecule that interacts with the fatty acid-binding pocket within the interior of FABP4 to inhibit binding of endogenous fatty acids. Treatment with BMS309403 has been shown to improve insulin resistance, diabetes mellitus, fatty liver disease and atherosclerosis in experimental models, indicating that chemical inhibition of FABP4 could be a therapeutic strategy against several aspects of metabolic syndrome (Fig. 3). Recent studies have also demonstrated that neutralization of secreted FABP4 with an antibody to FABP4 could be a feasible approach for treatment of insulin resistance, type 2 diabetes mellitus and vascular injury.

FABP5 as an FABP4-Related Lipid Chaperone

FABP5, another FABP known as epidermal FABP (E-FABP), psoriasis-associated FABP (PA-FABP) or mal, is expressed most abundantly in epidermal cells of the skin but is also present in several tissues and cells including adipocytes. FABP4 and FABP5 have 52% amino acid similarity and bind to several fatty acids with similar affinity and selectivity. The amount of FABP4 in adipocytes is about 100-fold larger than that of FABP5 in adipocytes. Both FABP4 and FABP5 are also expressed in macrophages and dendritic cells, though the amount of FABP4 in adipocytes is about 10,000-fold larger than that in macrophages. The stoichiometry of FABP4 and that of FABP5 are nearly equal in macrophages under physiological conditions. FABP4 deficiency induces a strong compensatory increase of FABP5 in adipose tissue but not in macrophages or dendritic cells. Other than adipocytes and macrophages, FABP5 is coexpressed with FABP4 in microvascular endothelial cells in the heart and kidney and even in endothelial cells of larger blood vessels. Similar to FABP4, FABP5 facilitates transendothelial transport of fatty acids into fatty acid-consuming organs.

Expression of FABP5 in macrophages is increased by treatment with toll-like receptor (TLR) agonists: LPS, a TLR4 agonist, and zymosan, a fungal product that activates TLR2. Expression of FABP5 in endothelial cells is induced by cellular senescence and H$_2$O$_2$-induced oxidative stress. In contrast to FABP4, FABP5 is not induced by VEGF-A or bFGF in endothelial cells. FABP5, similar to FABP4, in endothelial cells promotes angiogenic responses, but FABP5 can also exert opposing effects on endothelial survival, indicating that the balance between FABP4 and FABP5 in endothelial cells may be important for the regulation of angiogenic versus quiescent phenotypes in blood vessels.

FABP5 transgenic mice in adipose tissue on a high-fat diet show enhanced basal and hormone-stimulated lipolysis and reduced insulin sensitivity. On the other hand, FABP5 deficiency mildly increases systemic insulin sensitivity in dietary and genetic obesity mouse models. Ablation of FABP5 suppresses...
atherosclerosis in LDL receptor-deficient mice on a western-style hypercholesterolemic diet, and the anti-atherosclerotic effect of FABP5 deletion is associated with reduction of inflammatory response\textsuperscript{152}.

Secretome analyses showed that FABP5 is also secreted from cells\textsuperscript{62, 111, 153}, though the mechanism remains unclear. Transcriptome and metabolome analyses showed that exogenous FABP4 and FABP5 differentially affect transcriptional and metabolic regulation in adipose-derived stem cells near adipocytes\textsuperscript{153}. Circulating FABP5 has been reported to be detected at levels of about one tenth or less of circulating FABP4 concentrations, and FABP5 levels are associated with components of metabolic syndrome, although the correlation is not as strong as that of FABP4\textsuperscript{70, 154}. Interestingly, the concentration of FABP5, but not FABP4, is negatively and independently correlated with cholesterol efflux capacity from macrophages, the first step in the reverse cholesterol transport pathway, suggesting a potential biomarker for residual risk of atherosclerosis\textsuperscript{155}.

**Phenotype of Combined Deficiency of FABP4 and FABP5**

Mice with combined deficiency of FABP4 and FABP5 (\textit{Fabp4}\textsuperscript{-/-} \textit{Fabp5}\textsuperscript{-/-}) exhibit protection against type 2 diabetes, fatty liver disease and atherosclerosis more than do FABP4- or FABP5-deficient mice\textsuperscript{156-158}. The effects of FABP4 and FABP5 on atherosclerosis are mainly due to their actions in macrophages\textsuperscript{13, 152}. On the other hand, actions of FABP4 and FABP5 in adipocytes and those in macrophages have distinct roles in regulation of insulin sensitivity through metabolic and inflammatory responses\textsuperscript{62}. Calorie restriction prevents age-related metabolic disease and extends life span\textsuperscript{159}, and it shares many molecular features in combined deficiency of FABP4 and FABP5, but \textit{Fabp4}\textsuperscript{-/-} \textit{Fabp5}\textsuperscript{-/-} mice do not have increased longevity\textsuperscript{160}, indicating that extension of a metabolically healthy span in the absence of calorie restriction can be uncoupled from lifespan. It has also been demonstrated that \textit{Fabp4}\textsuperscript{-/-} \textit{Fabp5}\textsuperscript{-/-} mice have defective uptake of fatty acid via capillary endothelial cells of the heart and skeletal muscle with compensatory up-regulation of glucose consumption in those tissues during fasting\textsuperscript{161}. Furthermore, \textit{Fabp4}\textsuperscript{-/-} \textit{Fabp5}\textsuperscript{-/-} mice show impaired thermogenesis after cold exposure during fasting\textsuperscript{162}.

Lipidomic analyses showed increased \textit{de novo} lipogenesis by induction of stearoyl-CoA desaturase-1 (SCD-1) and fatty acid synthase in adipose tissue of \textit{Fabp4}\textsuperscript{-/-} \textit{Fabp5}\textsuperscript{-/-} mice, leading to identification of increased palmitoleate (C16:1n7), an unsaturated free fatty acid, as an adipose tissue-derived lipid hormone, referred to as ‘lipokine’, that can decrease fatty liver and increase glucose uptake in skeletal muscle\textsuperscript{163}. Deletion of FABP4 in macrophages also increases \textit{de novo} lipogenesis pathways through LXR\alpha-mediated SCD-1 activation, resulting in production of palmitoleate and resistance to ER stress\textsuperscript{164}. Unsaturated fatty acids including palmitoleate modulate histone deacetylation, resulting in decreased basal and LPS-induced expression levels of FABP4 in macrophages\textsuperscript{165}. Treatment with palmitoleate prevents atherosclerosis in ApoE-deficient mice in relation to reduced ER stress and inflammasome activation\textsuperscript{166}. In a human study, palmitoleate level was positively correlated with insulin sensitivity assessed by euglycemic-hyperinsulinemic clamp studies after adjustment of age, gender and adiposity\textsuperscript{167}. The level of the trans isomer of palmitoleate, an exogenous source of C16:1n7, was associated with lower insulin resistance and lower incidence of diabetes mellitus\textsuperscript{168}.

**Perspectives and Conclusion**

FABP4 is mainly expressed in adipocytes and macrophages and plays important roles in the development of insulin resistance and atherosclerosis in relation to metabolically driven low-grade and chronic inflammation, referred to as ‘metaflammation’\textsuperscript{21} (Fig. 1). FABP4 is involved in the regulation of inflammatory and metabolic processes in target cells (Fig. 2). The presence of FABP4 in cells may be beneficial for storing energy in adipocytes, for acting on an immune response in macrophages against pathogens, and for trafficking of fatty acids in capillary endothelial cells. Additionally, secreted FABP4 in association with lipolysis during fasting may regulate hepatic glucose production for survival in a famine. In the contemporary life-style with excessive caloric intake and decreased energy expenditure, the presence and induction of FABP4 or enhanced secretion of conformation-changed FABP4, which can bind to palmitic acid with a relatively high affinity\textsuperscript{35}, may be rather disadvantageous for regulating inflammatory or metabolic homeostasis. In such conditions, inhibition of FABP4, neutralization/elimination of secreted FABP4 or the use of possible antagonists for unidentified receptors of FABP4 could be an effective therapeutic strategy against metabolic and cardiovascular diseases and possibly other diseases (Fig. 3). Further studies are obviously needed to investigate whether chemical or other types of inhibition/neutralization of FABP4 and blocking receptors of FABP4 can be safely used in humans and to show the efficacy of agents for metabolic and cardiovascular diseases. Furthermore, other
than FABP4, several types of FABP inhibitors have been identified\(^{169,170}\), but there have been few detailed examinations using these inhibitors in \textit{in vivo} and \textit{in vitro} studies. Not only FABP4 but also other FABPs, including FABP5, may offer targeting opportunities as a class for prevention or treatment of other diseases. Much work is still needed to determine the precise applications and indications for other isoforms.

**Acknowledgements**

In relation to this review article, M.F. has been supported by grants from JSPS KAKENHI, MEXT Translational Research Network Program, Uehara Memorial Foundation, SENSHIN Medical Research Foundation, Japan Diabetes Foundation, Takeda Medical Research Foundation, Ono Medical Research Foundation, Takeda Science Foundation, Akiyama Life Science Foundation, Yamaguchi Endocrine Research Foundation, Naito Foundation Natural Science Scholarship, Suhara Memorial Foundation, Kon-dou Kinen Medical Foundation and Terumo Foundation for Life Science and Arts. The author is grateful to group members of our department for their scientific contribution and is deeply honored to receive Yuichiro Goto Award of the Japan Atherosclerosis Society in 2018. The author also regrets the inadvertent omission of many important references due to space limitations.

**Conflict of Interest**

None.

**References**

1) Gregor MF, Hotamisligil GS: Inflammatory mechanisms in obesity. Annu Rev Immunol, 2011; 29: 415-445
2) Hotamisligil GS: Inflammation, metaflammation and immunometabolic disorders. Nature, 2017; 542: 177-185
3) Furuhashi M, Hotamisligil GS: Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov, 2008; 7: 489-503
4) Furuhashi M, Ishimura S, Ota H, Miura T: Lipid chaperones and metabolic inflammation. Int J Inflamm, 2011; 2011: 642612
5) Furuhashi M, Saitoh S, Shimamoto K, Miura T: Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases. Clin Med Insights Cardiol, 2014; 8: 23-33
6) Hotamisligil GS, Bernlohr DA: Metabolic functions of FABPs--mechanisms and therapeutic implications. Nat Rev Endocrinol, 2015; 11: 592-605
7) Chmurzynska A: The multigene family of fatty acid-binding proteins (FABPs): function, structure and polymorphism. J Appl Genet, 2006; 47: 39-48
8) Amri EZ, Bertrand B, Ailhaud G, Grimaldi P: Regulation of adipose cell differentiation. I. Fatty acids are inducers of the aP2 gene expression. J Lipid Res, 1991; 32: 1449-1456
9) Cook JS, Lucas JJ, Sibley E, Bolanowski MA, Christy RJ, Kelly TJ, Lane MD: Expression of the differentiation-induced gene for fatty acid-binding protein is activated by glucocorticoid and cAMP. Proc Natl Acad Sci U S A, 1988; 85: 2949-2953
10) Distel RJ, Robinson GS, Spiegelman BM: Fatty acid regulation of gene expression. Transcriptional and post-transcriptional mechanisms. J Biol Chem, 1992; 267: 5937-5941
11) Kletzen RF, Foellmi LA, Harris PK, Wyse BM, Clarke SD: Adipocyte fatty acid-binding protein: regulation of gene expression in vivo and in vitro by an insulin-sensitizing agent. Mol Pharmacol, 1992; 42: 558-562
12) Melki SA, Abumrad NA: Expression of the adipocyte fatty acid-binding protein in streptozotocin-diabetes: effects of insulin deficiency and supplementation. J Lipid Res, 1993; 34: 1527-1534
13) Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, Parker RA, Suttles J, Fazio S, Hotamisligil GS, Linton MF: Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med, 2001; 7: 699-705
14) Yu F, Luo N, Lopes-Virella MF, Garvey WT: The adipocyte lipid binding protein (ALBP/aP2) gene facilitates foam cell formation in human THP-1 macrophages. Atherosclerosis, 2002; 165: 259-269
15) Kazemi MR, McDonald CM, Shigenaga JK, Grunfeld C, Feingold KR: Adipocyte fatty acid-binding protein expression and lipid accumulation are increased during activation of murine macrophages by toll-like receptor agonists. Arterioscler Thromb Vasc Biol, 2005; 25: 1220-1224
16) Pelton PD, Zhou L, Demarest KT, Burris TP: PPARgamma activation induces the expression of the adipocyte fatty acid binding protein gene in human monocytes. Biochem Biophys Res Commun, 1999; 261: 456-458
17) Yu F, Luo N, Lopes-Virella MF: Oxidized LDL induces the expression of ALBP/aP2 mRNA and protein in human THP-1 macrophages. J Lipid Res, 2000; 41: 2017-2023
18) Rolph MS, Young TR, Shum BO, Gorgun CZ, Schnitz PEiffer C, Ramshaw IA, Hotamisligil GS, Mackay CR: Regulation of dendritic cell function and T cell priming by the fatty acid-binding protein AP2. J Immunol, 2006; 177: 7794-7801
19) Furuhashi M, Hiramitsu S, Mita T, Omori A, Fuseya T, Ishimura S, Watanabe Y, Hoshina K, Matsumoto M, Tanaka M, Moniwa N, Yoshida H, Ishii J, Miura T: Reduction of circulating FABP4 level by treatment with omega-3 fatty acid ethyl esters. Lipids Health Dis, 2016; 15: 5
20) Furuhashi M, Hiramitsu S, Mita T, Fuseya T, Ishimura S, Omori A, Matsumoto M, Watanabe Y, Hoshina K, Tanaka M, Moniwa N, Yoshida H, Ishii J, Miura T:
Reduction of serum FABP4 level by sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes mellitus. J Lipid Res, 2015; 56: 2372-2380

21) Llaverias G, Noe V, Penuelas S, Vazquez-Carrera M, Sanchez RM, Laguna JC, Ciudad CJ, Alegrin M: Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages. Biochem Biophys Res Commun, 2004; 318: 265-274

22) Song J, Ren P, Zhang L, Wang XL, Chen L, Shen YH: Metformin reduces lipid accumulation in macrophages by inhibiting FOXO1-mediated transcription of fatty acid-binding protein 4. Biochem Biophys Res Commun, 2010; 393: 89-94

23) Garin-Shkolnik T, Rudich A, Hotamisligil GS, Rubinstein M: FABP4 attenuates PPAR gamma and adipogenesis and is inversely correlated with PPARgamma in adipose tissues. Diabetes, 2014; 63: 900-911

24) Ross SR, Graves RA, Greenstein A, Platt KA, Shyu HL, Mellovitz B, Spiegelman BM: A fat-specific enhancer is the primary determinant of gene expression for adipocyte P2 in vivo. Proc Natl Acad Sci U S A, 1990; 87: 9590-9594

25) Tontonoz P, Hu E, Graves RA, Budavari Al, Spiegelman BM: mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev, 1994; 8: 1224-1234

26) Christy RJ, Yang VW, Tnambi JM, Geiman DE, Landschulz WH, Friedman AD, Nakabeppu Y, Kelly TJ, Lane MD: Differentiation-induced gene expression in 3T3-L1 preadipocytes: CCAAT/enhancer binding protein interacts with and activates the promoters of two adipocyte-specific genes. Genes Dev, 1989; 3: 1323-1335

27) Rauscher FJ, 3rd, Sambucetti LC, Curran T, Distel RJ, Spiegelman BM: Common DNA binding site for Fos specific genes. Genes Dev, 1989; 3: 1323-1335

28) Ayers SD, Nedrow KL, Gillilan RE, Noy N: Continuous nucleocytoplasmic shuttling underlies transcriptional activation of PPARgamma by FABP4. Biochemistry, 2007; 46: 6744-6752

29) Gillilan RE, Ayers SD, Noy N: Structural basis for activation of fatty acid-binding protein 4. J Mol Biol, 2007; 372: 1246-1260

30) Smith AJ, Sanders MA, Juhlmann BE, Hertzyl AV, Bernlohr DA: Mapping of the hormone-sensitive lipase binding site on the adipocyte fatty acid-binding protein (AFABP). Identification of the charge quartet on the AFABP/aP2 helix-turn-helix domain. J Biol Chem, 2008; 283: 33536-33543

31) Scheja L, Makowski L, Uysal KT, Wiesbrock SM, Shimshek DR, Meyers DS, Morgan M, Parker RA, Hotamisligil GS: Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice. Diabetes, 1999; 48: 1987-1994

32) Shen WJ, Sridhar K, Bernlohr DA, Kraemer FB: Interaction of rat hormone-sensitive lipase with adipocyte lipid-binding protein. Proc Natl Acad Sci U S A, 1999; 96: 5528-5532

33) Hofer P, Boeszoermenyi A, Jaeger D, Feiler U, Arthanari R, Zechner R, Preiss-Landl K: Fatty Acid-binding Proteins Catalyzing Lipolysis with Lipid Ligand Shuttling. J Biol Chem, 2015; 290: 18438-18453

34) Thompson BR, Mazurkiewicz-Munoz AM, Suttles J, Carter-Su C, Bernlohr DA: Interaction of adipocyte fatty acid-binding protein (AFABP) and JAK2: AFABP/aP2 as a regulator of JAK2 signaling. J Biol Chem, 2009; 284: 13473-13480

35) Gorbenco O, Panayotou G, Zhyvoloup A, Volkova D, Gout I, Filonenko V: Identification of novel PTEN-binding partners: PTEN interaction with fatty acid binding protein FABP4. Mol Cell Biochem, 2010; 337: 299-305
45) Tsuda M, Inoue-Narita T, Suzuki A, Itami S, Blumenberg M, Manabe M: Induction of gene encoding FABP4 in Pten-null keratinocytes. FEBS Lett, 2009; 583: 1319-1322

46) Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papiaannou VE, Spiegelman BM: Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science, 1996; 274: 1377-1379

47) Uysal KT, Schjea L, Wiesbrock SM, Bonner-Weir S, Hotamisligil GS: Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology, 2000; 141: 3388-3396

48) Yang R, Castriota G, Chen Y, Cleary MA, Ellsworth K, Makowski L, Brittingham KC, Reynolds JM, Suttles J, Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Uysal KT, Scheja L, Wiesbrock SM, Bonner-Weir S, Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Cao H, Saatcioglu F, Hotamisligil GS: Secretion of adipocyte fatty acid-binding protein aP2 from adipocytes through MP, Cao H, Saatcioglu F, Hotamisligil GS: Secretion of adenyl cyclase-PKA- and guanylyl cyclase-PKG-dependent c-Jun NH2-terminal kinases and activator protein-1. J Biol Chem, 2010; 285: 10273-10280

49) Hui X, Li H, Zhou Z, Lam KS, Xiao Y, Wu D, Ding K, Zhang BB, Berger JP, Qureshi SA: RNAi-mediated germline knockdown of FABP4 increases body weight but does not improve the deranged nutrient metabolism of diet-induced obese mice. Int J Obes (Lond), 2011; 35: 217-225

50) Makowski L, Brittingham KC, Reynolds JM, Suttles J, Hotamisligil GS: The fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia. Arterioscler Thromb Vasc Biol, 2002; 22: 1686-1691

51) Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF, Hotamisligil GS: Adipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia. Arterioscler Thromb Vasc Biol, 2002; 22: 1686-1691

52) Hui X, Li H, Zhou Z, Lam KS, Xiao Y, Wu D, Ding K, Wang Y, Vanhoutte PM, Xu A: Adipocyte fatty acid-binding protein modulates inflammatory responses in macrophages through a positive feedback loop involving c-Jun NH2-terminal kinases and activator protein-1. J Biol Chem, 2010; 285:10273-10280

53) Xu H, Hertzov AV, Steen KA, Bernlohr DA: Loss of Fatty Acid Binding Protein 4/aP2 Reduces Macrophage Redox Signaling and Inflammasome Activation. Mol Cell Biol, 2017; 37: 217-225

54) Cao H, Sekiya M, Ertunc ME, Burak MF, Mayers JR, White A, Inouye K, Rickey LM, Erkal BC, Furuhashi M, Tuncman G, Hotamisligil GS: Adipocyte lipid chaperone aP2 is a secreted adipokine regulating hepatic glucose production. Cell Metab, 2013; 17: 768-778

55) Mita T, Furuhashi M, Hiramitsu S, Ishii J, Hoshina K, Ishimura S, Fuseya T, Watanabe Y, Tanaka M, Ohno K, Akasaka H, Ohnishi H, Yoshida H, Saihoh S, Shimamoto K, Miura T: FABP4 is secreted from adipocytes by adenyl cyclase-PKA- and guanylyl cyclase-PKG-dependent lipolytic mechanisms. Obesity (Spring), 2015; 23: 359-367

56) Ertunc ME, Sikkeland J, Fenaroli F, Griffiths G, Daniels MP, Cao H, Saatcioglu F, Hotamisligil GS: Secretion of fatty acid binding protein aP2 from adipocytes through a nonclassical pathway in response to adipocyte lipase activity. J Lipid Res, 2015; 56: 423-434

57) Schlottmann I, Ehrhart-Bornstein M, Wabitsch M, Bornstein SR, Lamounier-Zepter V: Calcium-dependent release of adipocyte fatty acid binding protein from human adipocytes. Int J Obes (Lond), 2014; 38: 1221-1227

58) Lamounier-Zepter V, Look C, Alvarez J, Christ T, Ravens U, Schunk WH, Ehrhart-Bornstein M, Bornstein SR, Morano I: Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: a new link between obesity and heart disease. Circ Res, 2009; 105: 326-334

59) Kralisch S, Ebert T, Lossner U, Jessnitzer B, Stumvoll M, Fasshauer M: Adipocyte fatty acid-binding protein is released from adipocytes by a non-conventional mechanism. Int J Obes (Lond), 2014; 38: 1251-1254

60) Nickel W, Rabouille C: Mechanisms of regulated unconventional protein secretion. Nat Rev Mol Cell Biol, 2009; 10: 148-155

61) Villeneuve J, Bassaganyas L, Lepreuex S, Chirioutou M, Costet P, Ripoche J, Malhotra V, Schekman R: Unconventional secretion of FABP4 by endosomes and secretory lysosomes. J Cell Biol, 2018; 217: 649-665

62) Furuhashi M, Fucho R, Gorgun CZ, Tuncman G, Cao H, Hotamisligil GS: Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Invest, 2008; 118: 2640-2650

63) Bosquet A, Guaita-Esteruelas S, Saavedra P, Rodriguez-Calvo R, Heras M, Girona J, Masana L: Exogenous FABP4 induces endoplasmic reticulum stress in HepG2 liver cells. Atherosclerosis, 2016; 249: 191-199

64) Wu LE, Samocha-Bonet D, Whitworth PT, Fazakerley DJ, Turner N, Biden TJ, James DE, Cantley J: Identification of fatty acid binding protein 4 as an adipokine that regulates insulin secretion during obesity. Mol Metab, 2014; 3: 465-473

65) Guaita-Esteruelas S, Bosquet A, Saavedra P, Gumja J, Girona J, Lam EW, Amillano K, Borras J, Masana L: Exogenous FABP4 increases breast cancer cell proliferation and activates the expression of fatty acid transport proteins. Mol Carcinog, 2017; 56: 208-217

66) Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda S, Shimomura I: Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest, 2004; 114: 1752-1761

67) Saavedra P, Girona J, Bosquet A, Guaita S, Canela N, Aragones G, Heras M, Masana L: New insights into circulating FABP4: Interaction with cytokeratin 1 on endothelial cell membranes. Biochim Biophys Acta, 2015; 1853: 2966-2974

68) Martinez-Micaelo N, Rodriguez-Calvo R, Guaita-Esteruelas S, Heras M, Girona J, Masana L: Extracellular FABP4 uptake by endothelial cells is dependent on cyto- keratin 1 expression. Biochim Biophys Acta Mol Cell Biol Lipids, 2018; 227
glomerular filtration followed by megalin-mediated reabsorption. Sci Rep, 2018; 8: 16451
70) Ishimura S, Furuhashi M, Watanabe Y, Hoshina K, Fuseya T, Mita T, Okazaki Y, Koyama M, Tanaka M, Akasaka H, Ohnishi H, Yoshida H, Saitoh S, Miura T: Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general population. PLoS One, 2013; 8: e81318
71) Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, Wat NM, Wong WK, Lam KS: Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem, 2006; 52: 405-413
72) Hu X, Ma X, Pan X, Luo Y, Xu Y, Xiong Q, Bao Y, Jia W: Association of androgen with gender difference in serum adipocyte fatty acid binding protein levels. Sci Rep, 2016; 6: 27762
73) Iso T, Sunaga H, Matsui H, Kasama S, Oshima N, Haruyama H, Furuhashi M, Nakajima K, Machida T, Murakami M, Yokoyama T, Kurabayashi M: Serum levels of fatty acid binding protein 4 and fat metabolic markers in relation to catecholamines following exercise. Clin Biochem, 2017; 50: 896-902
74) Choi KM, Kim TN, Yoo HJ, Lee KW, Cho GJ, Hwang TG, Baik SH, Choi DS, Kim SM: Effect of exercise training on A-FABP, lipocalin-2 and RBP4 levels in obese women. Clin Endocrinol (Oxf), 2009; 70: 569-574
75) Simon I, Escote X, Vilarrasa N, Gomez J, Fernandez-Real JM, Megia A, Gutierrez C, Gallart L, Masdevall C, Vendrell J: Adipocyte fatty acid-binding protein as a determinant of insulin sensitivity in morbid-obese women. Obesity (Silver Spring), 2009; 17: 1124-1128
76) Terra X, Quintero Y, Auguet T, Porras JA, Hernandez M, Sabench F, Aguilar C, Luna AM, Del Castillo D, Richart C: FABP4 is associated with inflammatory markers and metabolic syndrome in morbidly obese women. Eur J Endocrinol (Oxf), 2009; 70: 569-574
77) Fisher RM, Eriksson P, Hoffstedt J, Hotamisligil GS, Thorne A, Ryden M, Hamsten A, Arner P: Fatty acid binding protein expression in different adipose tissue depots from lean and obese individuals. Diabetologia, 2001; 44: 1268-1273
78) Lee JJ, Britton KA, Pedley A, Massaro JM, Speliotes EK, Murabito JM, Hoffmann U, Ingram C, Keaney JF Jr., Vasan RS, Fox CS: Adipose Tissue Depots and Their Cross-Sectional Associations With Circulating Biomarkers of Metabolic Regulation. J Am Heart Assoc, 2016; 5:
79) Wajchenberg BL: Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev, 2000; 21: 697-738
80) Miehle K, Ebert T, Kralisch S, Hoffmann A, Kratzsch J, Schlogl H, Stumvoll M, Fasshauer M: Adipocyte and epidemial fatty acid-binding protein serum concentrations in patients with lipodystrophy. Cytokine, 2017; 92: 20-23
81) Carlsson AC, Ingelsson E, Sundstrom J, Carrero JJ, Gustafsson S, Feldreich T, Stenemo M, Larsson A, Lind L, Arnlov J: Use of Proteomics To Investigate Kidney Function Decline over 5 Years. Clin J Am Soc Nephrol, 2017; 12: 1226-1235
82) Furuhashi M, Ishimura S, Ota H, Hayashi M, Nishitani T, Tanaka M, Yoshida H, Shimamoto K, Hotamisligil GS, Miura T: Serum fatty acid-binding protein 4 is a predictor of cardiovascular events in end-stage renal disease. PLoS One, 2011; 6: e27356
83) Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH, Yeung DC, Janus ED, Sham PC, Lam KS: Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation, 2007; 115: 1537-1543
84) Nakamura R, Okura T, Fujikoya J, Sumi K, Matsuzawa K, Izawa S, Ueta E, Kato M, Taniguchi SI, Yamamoto K: Serum fatty acid-binding protein 4 (FABP4) concentration is associated with insulin resistance in peripheral tissues, A clinical study. PLoS One, 2017; 12: e0179737
85) Tso AW, Xu A, Sham PC, Wat NM, Wang Y, Fong CH, Cheung BM, Janus ED, Lam KS: Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care, 2007; 30: 2667-2672
86) Ota H, Furuhashi M, Ishimura S, Koyama M, Okazaki Y, Mita T, Fuseya T, Yamashita T, Tanaka M, Yoshida H, Shimamoto K, Miura T: Elevation of fatty acid-binding protein 4 is predisposed by family history of hypertension and contributes to blood pressure elevation. Am J Hypertens, 2012; 25: 1124-1130
87) Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, Heras M, Masana L: Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes. J Lipid Res, 2008; 49: 1746-1751
88) Yeung DC, Xu A, Cheung CW, Wat NM, Yau MH, Fong CH, Chau MT, Lam KS: Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol, 2007; 27: 1796-1802
89) Fuseya T, Furuhashi M, Yuda S, Muranaka A, Kawamura K, Mita T, Ishimura S, Watanabe Y, Hoshina K, Tanaka M, Ohno K, Akasaka H, Ohnishi H, Yoshida H, Saitoh S, Shimamoto K, Miura T: Elevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population. Cardiovasc Diabetol, 2014; 13: 126
90) Rodrigo-Calvo R, Girona J, Alegret JM, Bosquet A, Ibarretxe D, Masana L: Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease. J Endocrinol, 2017; 233: R173-R184
91) Nishino T, Okamoto K: Mechanistic insights into xanthine oxidoreductase from development studies of candidate drugs to treat hyperuricemia and gout. J Biol Inorg Chem, 2015; 20: 195-207
92) Furuhashi M, Matsumoto M, Tanaka M, Moniwa N, Murase T, Nakamura T, Ohnishi H, Saitoh S, Shimamoto K, Miura T: Plasma Xanthine Oxidoreductase Activity as a Novel Biomarker of Metabolic Disorders in a General Population. Circ J, 2018; 82: 1892-1899
93) Furuhashi M, Mori K, Tanaka M, Maeda T, Matsumoto M, Murase T, Nakamura T, Koyama M, Moniwa N, Ohnishi H, Saitoh S, Shimamoto K, Miura T: Unexpected high plasma xanthine oxidoreductase activity in female subjects with low levels of uric acid. Endocr J,
94) Furuhashi M, Matsumoto M, Murase T, Nakamura T, Higashiura Y, Koyama M, Tanaka M, Moniwa N, Ohnishi H, Saitoh S, Shimamoto K, Miura T: Independent links between plasma xanthine oxidoreductase activity and levels of adipokines. J Diabetes Investig, 2018 Dec 5. doi: 10.1111/jdi.12982. [Epub ahead of print]

95) Furuhashi M, Omori A, Matsumoto M, Kataoka Y, Tanaka M, Moniwa N, Ohnishi H, Yoshida H, Saitoh S, Shimamoto K, Miura T: Independent Link Between Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and FABP4 in a General Population Without Medication. Am J Cardiol, 2016; 118: 198-203

96) Furuhashi M, Yuda S, Muranaka A, Kawamukai M, Matsumoto M, Tanaka M, Moniwa N, Ohnishi H, Saitoh S, Shimamoto K, Miura T: Circulating Fatty Acid-Binding Protein 4 Concentration Predicts the Progression of Carotid Atherosclerosis in a General Population Without Medication. Circ J, 2018; 82: 1121-1129

97) von Eynatten M, Breitling LP, Roos M, Baumann M, Rothenbacher D, Brenner H: Circulating adipocyte fatty acid-binding protein levels and cardiovascular morbidity and mortality in patients with coronary heart disease: a 10-year prospective study. Arterioscler Thromb Vasc Biol, 2012; 32: 2327-2335

98) Chow WS, Tso AW, Xu A, Yuen MM, Fong CH, Lam TH, Lo SV, Tse HF, Woo YC, Yeung CY, Cheung BM, Lam KS: Elevated circulating adipocyte-fatty acid binding protein levels predict incident cardiovascular events in a community-based cohort: a 12-year prospective study. J Am Heart Assoc, 2013; 2: e004176

99) Liu G, Ding M, Chiuve SE, Rimm EB, Franks PW, Meigs JB, Hu FB, Sun Q: Plasma Levels of Fatty Acid-Binding Protein 4, Retinol-Binding Protein 4, High-Molecular-Weight Adiponectin, and Cardiovascular Mortality Among Men With Type 2 Diabetes: A 22-Year Prospective Study. Arterioscler Thromb Vasc Biol, 2016; 36: 2259-2267

100) Szasz T, Webb RC: Perivascular adipose tissue: more than just structural support. Clin Sci (Lond), 2012; 122: 1-12

101) Numaguchi R, Furuhashi M, Matsumoto M, Sato H, Yanase Y, Kuroda Y, Harada R, Ito T, Higashiura Y, Koyama M, Tanaka M, Moniwa N, Nakamura M, Doi H, Miura T, Kawaharada N: Differential phenotypes in perivascular adipose tissue surrounding the internal thoracic artery and diseased coronary artery. J Am Heart Assoc, 2019; 8: e011147

102) Vural B, Atalar F, Ciftci C, Demirkan A, Susleyici-Duman B, Gunay D, Akpinar B, Sagbas E, Ozbek U, Buyukdevrim AS: Presence of fatty-acid-binding protein 4 expression in human epicardial adipose tissue in metabolic syndrome. Cardiovasc Pathol, 2008; 17: 392-398

103) Elie A, Bloksgaard M, Sun WY, Yang K, Man AWC, Xu A, Irmukhamedov A, Riber LP, Wang Y, De Mey JGR: Local enrichment of fatty acid-binding protein 4 in the pericardial cavity of cardiovascular disease patients. PLoS One, 2018; 13: e0206802

104) Obokata M, Iso T, Ohyama Y, Sunaga H, Kawaguchi T, Matsu H, Iizuka T, Fukuda N, Takamatsu H, Koizabashi N, Funada R, Takama N, Kasama S, Kaneko Y, Yokoyama T, Murakami M, Kurabayashi M: Early increase in serum fatty acid binding protein 4 levels in patients with acute myocardial infarction. Eur Heart J Acute Cardiovasc Care, 2018; 7: 561-569

105) Karpisek M, Stejskal D, Kotolova H, Kollar P, Janoutova G, Ochmanova R, Cizek L, Horakova D, Yahia RB, Lichnovska R, Janout V: Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia. Eur J Clin Invest, 2007; 37: 637-642

106) Furuhashi M, Mita T, Moniwa N, Hoshina K, Ishimura S, Fuseya T, Watanabe Y, Yoshida H, Shimamoto K, Miura T: Angiotensin II receptor blockers decrease serum concentration of fatty acid-binding protein 4 in patients with hypertension. Hypertens Res, 2015; 38: 252-259

107) Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, Heras M, Masana L: Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis, 2007; 195: e150-158

108) Furuhashi M, Matsumoto M, Hiramitsu S, Omori A, Tanaka M, Moniwa N, Yoshida H, Ishii J, Miura T: Possible Increase in Serum FABP4 Level Despite Adiposity Reduction by Canagliflozin, an SGLT2 Inhibitor. PLoS One, 2016; 11: e0154482

109) Iso T, Maeda K, Hanaoka H, Suga T, Goto K, Syamsunnarno MR, Hishiki T, Nagahata Y, Matsu H, Arai M, Yamaguchi A, Abumrad NA, Sano M, Suematsu M, Endo K, Hotamisligil GS, Kurabayashi M: Capillary endothelial fatty acid binding proteins 4 and 5 play a critical role in fatty acid uptake in heart and skeletal muscle. Arterioscler Thromb Vasc Biol, 2013; 33: 2549-2557

110) Han Q, Yeung SC, Ip MSM, Mak JCW: Effects of intermittent hypoxia on A/-E-FABP expression in human aortic endothelial cells. Int J Cardiol, 2010; 145: 396-398

111) Hwang HH, Moon PG, Lee JE, Kim JG, Lee W, Ryu SH, Baek MC: Identification of the target proteins of rosiglitazone in 3T3-L1 adipocytes through proteomic analysis of cytosolic and secreted proteins. Mol Cells, 2011; 31: 239-246

112) Tanaka M, Furuhashi M, Okazaki Y, Mita T, Fuseya T, Ohno K, Ishimura S, Yoshida H, Miura T: Ectopic expression of fatty acid-binding protein 4 in the glomerulus is associated with proteinuria and renal dysfunction. Nephron Clin Pract, 2014; 128: 345-351

113) Yao F, Li Z, Ebara T, Yang L, Wang D, Feng L, Zhang Y, Wang K, Shi Y, Duan H, Zhang L: Fatty Acid-Binding Protein 4 mediates apoptosis via endoplasmic reticulum stress in mesangial cells of diabetic nephropathy. Mol Cell Endocrinol, 2015; 411: 232-242

114) Kamijo A, Kimura K, Sugaya T, Yamanouchi M, Hikawa A, Hirano N, Hirata Y, Goto A, Omata M: Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med, 2004; 143: 23-30

115) Okazaki Y, Furuhashi M, Tanaka M, Mita T, Fuseya T, Ishimura S, Watanabe Y, Hoshina K, Akasaka H, Ohnishi H, Yoshida H, Saitoh S, Shimamoto K, Miura T:
Urinary excretion of fatty acid-binding protein 4 is associated with albuminuria and renal dysfunction. PLoS One, 2014; 9: e115429

116) Ghelfi E, Karaaslan C, Berkelhamer S, Akar S, Kozake- wich H, Cataltepe S: Fatty acid-binding proteins and peribronchial angiogenesis in bronchopulmonary dysplasia. Am J Respir Cell Mol Biol, 2011; 45: 550-556

117) Mauer A, Medica I, Peterlin B: Search for sarcoidosis candidate genes by integration of data from genomic, transcriptomic and proteomic studies. Med Sci Monit, 2009; 15: SR22-28

118) Shum BO, Mackay CR, Gorgun CZ, Frost MJ, Kumar RK, Hotamisligil GS, Rolph MS: The adipocyte fatty acid-binding protein aP2 is required in allergic airway inflammation. J Clin Invest, 2006; 116: 2183-2192

119) Ghelfi E, Yu CW, Elmasri H, Terwelp M, Lee CG, Bhandari V, Comhair SA, Erzurum SC, Hotamisligil GS, Elias JA, Cataltepe S: Fatty acid binding protein 4 regulates VEGF-induced airway angiogenesis and inflammation in a transgenic mouse model: implications for asthma. Am J Pathol, 2013; 182: 1425-1433

120) Ge XN, Bastan I, Dileepan M, Greenberg Y, Ha SG, Steen KA, Bernlohr DA, Rao SP, Sirramarao P: FABP4 regulates eosinophil recruitment and activation in allergic airway inflammation. Am J Physiol Lung Cell Mol Physiol, 2018; 315: L227-L240

121) Duffy CM, Xu H, Nixon JP, Bernlohr DA, Butterick TA: Identification of a fatty acid binding protein4-UCP2 axis regulating microglial mediated neuroinflammation. Mol Cell Neurosci, 2017; 80: 52-57

122) Saint-Geniez M, Ghelfi E, Liang X, Yu C, Spencer C, Abend S, Hotamisligil G, Cataltepe S: Fatty acid binding protein 4 deficiency protects against oxygen-induced retinopathy in mice. PLoS One, 2014; 9: e96253

123) Wang Q, Shi G, Teng Y, Li X, Xie J, Shen Q, Zhang C, Ni S, Tang Z: Successful reduction of inflammatory responses and arachidonic acid-cyclooxygenase 2 pathway in human pulmonary artery endothelial cells by silencing adipocyte fatty acid-binding protein. J Inflammm (Lond), 2017; 14: 8

124) Hu B, Guo Y, Garbaczy WG, Jhang M, Xu M, Huang H, Tsung A, Billiar TR, Ramakrishnan SK, Shah YM, Lam KS, Huang M, Xie W: Fatty acid binding protein-4 (FABP4) is a hypoxia inducible gene that sensitizes mice to liver ischemia/reperfusion injury. J Hepatol, 2015; 63: 855-862

125) Scifres CM, Chen B, Nelson DM, Sadovsky Y: Fatty acid binding protein 4 regulates intracellular lipid accumulation in human trophoblasts. J Clin Endocrinol Metab, 2011; 96: E1083-1091

126) Nourani MR, Owada Y, Kitanaaka N, Sakagami H, Hoshi H, Iwasa H, Spener F, Kondo H: Occurrence of immunoreactivity for adipocyte-type fatty acid binding protein in degenerating granulosa cells in atretic antral follicles of mouse ovary. J Mol Histol, 2005; 36: 491-497

127) Hu W, Qiao J: Expression and regulation of adipocyte fatty acid binding protein in granulosa cells and its relation with clinical characteristics of polycystic ovary syndrome. Endocrine, 2011; 40: 196-202

128) Nieman KM, Kenny HA, Penicika CV, Ladanyi A, Buell- Gutbrod R, Zillhardt MR, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K, Lengyel E: Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med, 2011; 17: 1498-1503

129) Gharpure KM, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu SY, Bayraktar E, Nagaraja AS, Mangala LS, Zhang X, Haemmerle M, Hu W, Rodriguez-Aguayo C, McGuire M, Mak CSL, Chen X, Tran MA, Villar-Prados A, Pena GA, Kondetimmanahalli R, Nini R, Koppula P, Ram P, Liu J, Lopez-Berestein G, Baggery K, L SE, Sood AK: FABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun, 2018; 9: 2923

130) Bennett JH, Shousha S, Puddle B, Athanasou NA: Immunohistochemical identification of tumours of adipocytic differentiation using an antibody to aP2 protein. J Clin Pathol, 1995; 48: 950-954

131) Cataltepe O, Arikan MC, Ghelfi E, Karaaslan C, Ozsu- rekci Y, Dresser K, Li Y, Smith TW, Cataltepe S: Fatty acid binding protein 4 is expressed in distinct endothelial and non-endothelial cell populations in glioblastoma. Neuropathol Appl Neurobiol, 2012; 38: 400-410

132) Ohlsson G, Moreira JM, Gromov P, Sauter G, Celis JE: Loss of expression of the adipocyte-type fatty acid-binding protein (A-FABP) is associated with progression of human urothelial carcinomas. Mol Cell Proteomics, 2005; 4: 570-581

133) Kim S, Lee Y, Koo JS: Differential expression of lipid metabolism-related proteins in different breast cancer subtypes. PLoS One, 2015; 10: e0119473

134) Cha YJ, Kim HM, Koo JS: Expression of Lipid Metabo- lism-Related Proteins Differs between Invasive Lobular Carcinoma and Invasive Ductal Carcinoma. Int J Mol Sci, 2017; 18:

135) Huang M, Narita S, Inoue T, Koizumi A, Saito M, Tsu- ruta H, Numakura K, Sato N, Nano H, Sasaki T, Habuchi T: Fatty acid binding protein 4 enhances prostate cancer progression by upregulating matrix metalloproteinases and stromal cell cytokine production. Onco- target, 2017; 8: 111780-111794

136) Thompson KJ, Austin RG, Nazari SS, Gersin KS, Ian- nitti DA, McKillop IH: Altered fatty acid-binding protein aP2 in prostate cancer progression by upregulating matrix metalloproteinases and stromal cell cytokine production. Oncotarget, 2017; 8: 111780-111794

137) Zhong CQ, Zhang XP, Ma N, Zhang EB, Li JJ, YB, Gao YZ, Yuan YM, Lan SQ, Xie D, Cheng SQ: FABP4 suppresses proliferation and invasion of hepatocellular carcinoma. Liver Int, 2018; 38: 1074-1083

138) Chiyonobu N, Shimada S, Akiyama Y, Mogushi K, Itoh M, Akahoshi K, Matsumura S, Ogawa K, Ono H, Mitsu- nori Y, Ban D, Kudo A, Arii S, Suganami T, Yamaoka S, Ogawa Y, Tanabe M, Tyan S, Fatty Acid Binding Protein 4 (FABP4) Overexpression in Intrauterumal Hepatic Stellate Cells within Hepatocellular Carcinoma with Metabolic Risk Factors. Am J Pathol, 2018; 188: 1213-1224

139) Lee D, Wada K, Taniguchi Y, Al-Shareef H, Masuda T,
Usami Y, Aikawa T, Okura M, Kamisaki Y, Kogo M: Expression of fatty acid binding protein 4 is involved in the cell growth of oral squamous cell carcinoma. Oncol Rep, 2014; 31: 1116-1120

140) Jin J, Zhang Z, Zhang S, Chen X, Chen Z, Hu P, Wang J, Xie C: Fatty acid binding protein 4 promotes epithelial-mesenchymal transition in cervical squamous cell carcinoma through AKT/GSK3beta/Snail signaling pathway. Mol Cell Endocrinol, 2018; 461: 155-164

141) Tang Z, Shen Q, Xie H, Zhou X, Li J, Feng J, Liu H, Wang W, Zhang S, Ni S: Elevated expression of FABP3 and FABP4 cooperatively correlates with poor prognosis in non-small cell lung cancer (NSCLC). Oncotarget, 2016; 7: 46253-46262

142) Sulsky R, Magnin DR, Huang Y, Simpkins L, Taunp K, Patel M, Zhu Y, Stouch TR, Bassolino-Klimas D, Parker R, Harrity T, Stoffel R, Taylor DS, Lavoie TB, Kish K, Jacobson BL, Sheriff S, Adam LP, Ewing WR, Robl JA: Potent and selective biphylon azole inhibitors of adipocyte fatty acid binding protein (aFABP). Bioorg Med Chem Lett, 2007; 17: 3511-3515

143) Furuhashi M, Tuncan G, Gorgun CZ, Makowski L, Atsumi G, Vaillancourt E, Kono K, Babaev VR, Fazio S, Linton MF, Sulsky R, Robl JA, Parker RA, Hotamisligil GS: Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature, 2007; 447: 959-965

144) Hertzel AV, Hellberg K, Reynolds JM, Kruse AC, Juhl-Furuhashi M, Tuncan G, Gorgun CZ, Makowski L, Atsumi G, Vaillancourt E, Kono K, Babaev VR, Fazio S, Linton MF, Sulsky R, Robl JA, Parker RA, Hotamisligil GS: Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature, 2007; 447: 959-965

145) Hertzel AV, Hellberg K, Reynolds JM, Kruse AC, Juhlmann BE, Smith AJ, Sanders MA, Ohlendehf DH, Suttes J, Bernlohr DA: Identification and characterization of a small molecule inhibitor of Fatty Acid binding proteins. J Med Chem, 2009; 52: 6024-6031

146) Burak MF, Inouye KE, White A, Lee A, Tuncan G, Calay ES, Sekiya M, Tsushima Y, Endo K, Hotamisligil GS, Babaev VR, Fan D, Ding L, Zhang Y, Tao H, Erbay E, Gorgun CZ, Fazio S, Hotamisligil GS, Linton MF: Macrophage Mal1 deficiency suppresses atherosclerosis in low-density lipoprotein receptor-null mice by activating peroxisome proliferator-activated receptor-gamma-regulated genes. Arterioscler Thromb Vasc Biol, 2011; 31: 1283-1290

147) Yamamoto T, Furuhashi M, Sugaya T, Oikawa T, Matsumoto M, Funahashi Y, Matsukawa Y, Gotoh M, Miura T: Transcriptome and Metabolome Analyses in Exogenous FABP4- and FABP5-Treated Adipose-Derived Stem Cells. PLoS One, 2016; 11: e0167825

148) Yeung DC, Wang Y, Xu A, Cheung SC, Wat NM, Fong DY, Fong CH, Chau MT, Sham PC, Lam KS: Epidermal fatty-acid-binding protein: a new circulating biomarker associated with cardio-metabolic risk factors and carotid atherosclerosis. Eur Heart J, 2008; 29: 2156-2163

149) Furuhashi M, Ogura M, Matsumoto M, Yuda S, Muranaka A, Kawamukai M, Omori A, Tanaka M, Moniwa N, Ohnishi H, Saitoh S, Harada-Shiba M, Shimamoto K, Miura T: Serum FABP5 concentration is a potential biomarker for residual risk of atherosclerosis in relation to cholesterol efflux from macrophages. Sci Rep, 2017; 7: 217

150) Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M, Uysal KT, Cao Q, Atsumi G, Malone H, Krishnan B, Minokoshi Y, Kahn BB, Parker RA, Hotamisligil GS: Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab, 2005; 1: 107-119

151) Cao H, Maeda K, Gorgun CZ, Kim HK, Park SY, Shulman GI, Kim JK, Hotamisligil GS: Regulation of metabolic responses by adipocyte/macrophage Fatty Acid-binding proteins in leptin-deficient mice. Diabetes, 2006; 55: 1915-1922

152) Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF, Hotamisligil GS: Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation, 2004; 110: 1492-1498

153) Anderson RM, Weindruch R: Metabolic reprogramming, caloric restriction and aging. Trends Endocrinol Metab, 2010; 21: 134-141

154) Charles KN, Li MD, Engin F, Arruda AP, Inouye K, Hotamisligil GS: Uncoupling of Metabolic Health from Longevity through Genetic Alteration of Adipose Tissue Lipid-Binding Proteins. Cell Rep, 2017; 21: 393-402

155) Syamsunarno MR, Iso T, Hanaoka H, Yamaguchi A, Obokata M, Koitabashi N, Goto K, Hishiki T, Nagahata Y, Matsui H, Sano M, Kobayashi M, Kikuchi O, Sasaki T, Maeda K, Murakami M, Kitamura T, Suematsu M, Tsushima Y, Endo K, Hotamisligil GS, Kurabayashi M: A critical role of fatty acid binding protein 4 and 5 in obesity and insulin resistance. Diabetes, 2003; 52: 300-307
Nguyen UT, Watkins SM, Hotamisligil GS, Erbay E: Prevention of atherosclerosis by bioactive palmitoleate through suppression of organelle stress and inflammatory activation. Sci Transl Med, 2016; 8: 358ra126

167) Stefan N, Kantartzis K, Celebi N, Staiger H, Machann J, Schick F, Cegan A, Elcnerova M, Schleicher E, Fritsche A, Haring HU: Circulating palmitoleate strongly and independently predicts insulin sensitivity in humans. Diabetes Care, 2010; 33: 405-407

168) Mozaffarian D, Cao H, King IB, Lemaitre RN, Song X, Siscovick DS, Hotamisligil GS: Trans-palmitoleic acid, metabolic risk factors, and new-onset diabetes in U.S. adults: a cohort study. Ann Intern Med, 2010; 153: 790-799

169) Berger WT, Ralph BP, Kaczocha M, Sun J, Balisus TE, Rizzo RC, Haj-Dahmane S, Ojima I, Deutsch DG: Targeting fatty acid binding protein (FABP) anandamide transporters - a novel strategy for development of anti-inflammatory and anti-nociceptive drugs. PLoS One, 2012; 7: e50968

170) Wang YT, Liu CH, Zhu HL: Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015). Expert Opin Ther Pat, 2016; 26: 767-776